Please check your internet connection and try again.
# TabVoihep
## Overview
TabVoihep is a brand name for **velpatasvir/sofosbuvir**, an NS5A inhibitor and an NS5B polymerase inhibitor, respectively, used for the treatment of chronic Hepatitis C virus (HCV) infection.
## Primary Indications
Treatment of chronic Hepatitis C virus (HCV) infection in adults and pediatric patients 12 years of age or older and weighing at least 45 kg, genotypes 1, 2, 3, 4, 5, and 6.
## Adult Dosing
* **Standard Dose:** One tablet (velpatasvir 100 mg/sofosbuvir 400 mg) taken orally once daily.
* **Duration:** Typically 12 weeks. Duration may be extended to 24 weeks in patients with prior treatment failure, cirrhosis, or certain baseline characteristics as per specific treatment guidelines.
## Pediatric Dosing
* **Age/Weight:** Patients 12 years of age or older and weighing at least 45 kg.
* **Dose:** One tablet (velpatasvir 100 mg/sofosbuvir 400 mg) taken orally once daily.
* **Duration:** Typically 12 weeks.
## Dose Adjustments
No dose adjustment is required for adult patients based on renal or hepatic impairment. However, caution is advised in severe renal impairment and end-stage renal disease.
## Contraindications
* Concomitant use with potent P-glycoprotein (P-gp) inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.
## Adverse Effects
* **Common:** Headache, fatigue, nausea, insomnia, anemia.
* **Serious (less common):** Bradycardia (especially when used with amiodarone), reactivation of Hepatitis B virus (HBV) infection.
## Key Drug Interactions
* **Amiodarone:** Increased risk of severe symptomatic bradycardia. Monitor heart rate closely.
* **Antacids (aluminum or magnesium hydroxide):** Separate administration by at least 4 hours.
* **Anticonvulsants (carbamazepine, phenytoin):** Avoid; these are potent P-gp inducers and can significantly reduce velpatasvir/sofosbuvir exposure.
* **Rifampin:** Avoid; potent P-gp inducer.
* **St. John's Wort:** Avoid; potent P-gp inducer.
* **Bictegravir/Emtricitabine/Tenofovir Alafenamide:** Concurrent use is not recommended due to increased sofosbuvir and velpatasvir concentrations.
## Monitoring
* HCV viral load at baseline and post-treatment to assess viral cure (SVR12).
* Liver function tests.
* Hemoglobin and hematocrit if concurrent ribavirin is used or if bradycardia is a concern.
* HBV DNA testing in patients with risk factors for HBV coinfection prior to treatment initiation.
## Clinical Pearls
* TabVoihep is a pan-genotypic regimen effective across genotypes 1-6.
* It can be used in patients with compensated cirrhosis.
* The optimal duration of treatment depends on genotype, prior treatment history, and presence of cirrhosis. Always refer to current treatment guidelines for definitive duration.
* Ensure HBV screening is performed before initiating therapy due to the risk of HBV reactivation.
***
**Disclaimer:** This information is intended for healthcare professionals. Always verify current prescribing information and clinical guidelines before making treatment decisions.
